Eli Lilly and Co. and the Alzheimer's Association say that the CMS' proposal to limit coverage of a pricey new test used to identify brain plaques associated with Alzheimer's disease would hinder diagnosis. FULL STORY »
Hours after the U.S. Supreme Court invalidated Myriad Genetics' monopoly on testing for two breast cancer genes, the company's stock went tumbling as competitors announced plans to offer the same services at lower prices. FULL STORY »
Tim Weaver, an 18-year-old college student who lives in Naperville, Ill., is one of the estimated 30,000 people in the U.S. who rely on intravenous nutrition products to keep them alive. FULL STORY »
Patrick Lukulay faced a daunting task this month when he stepped off a plane in Accra, Ghana. Local clinics were reporting that oxytocin, a drug used to stop hemorrhaging after childbirth, was no longer working. FULL STORY »
A showdown is shaping up between federal healthcare privacy regulators and the nation's largest pharmacies and pharmaceutical manufacturers over a healthcare privacy rule affecting upwards of 100 million prescription-refill reminders sent to patients each year. FULL STORY »
By Beth Kutscher | April 13, 2013
| Print Magazine
Hospital chains, health insurers and retail pharmacy groups are likely to wind up big winners in any shakeup of the corporate tax code, while pharmaceutical companies and medical-device makers may find themselves fighting tooth and nail to keep the status quo. FULL STORY »
Desperate after a decade of trial and error to make the connection that could usher in a new generation of anti-HIV drugs, University of Washington researchers threw the scientific version of a Hail Mary pass. FULL STORY »
A patient balks at paying $50 for a dose of antibiotics. However, that same patient has no issue paying $50,000 for an oncology drug that may extend life for a few weeks. FULL STORY »
By Melanie Evans | January 26, 2013
| Print Magazine
Last year, the Utah-based SelectHealth insurance company paid $1 million to provide just five patients with the critical enzyme-replacement drug Cerezyme. FULL STORY »
At least seven of the 35 new drugs approved by the Food and Drug Administration last year cost $9,000 or more per month as manufacturers turn to developing high-priced specialty drugs to shore up bottom lines eroding from the expiration of patents on best-selling drugs that treat common conditions. FULL STORY »
Switch to the new Modern Healthcare Daily News app
For the best experience of ModernHealthcare.com on your iPad, switch to the new Modern Healthcare app — it's optimized for your device but there is no need to download.
